Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Wang G, Sun X, Zuo S, Li C, Niu Q, Xia Y, Meng Y, Liu M, Fang Z, Yang X, Jiang Y, Wang S, Cui H, Huang H, Jiang E, Zhou D, Deng Q, Pan J, Feng X.
Wang G, et al. Among authors: meng y.
J Hematol Oncol. 2021 Sep 16;14(1):149. doi: 10.1186/s13045-021-01160-9.
J Hematol Oncol. 2021.
PMID: 34530888
Free PMC article.